At Amunix, we are focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness the immune system, we aim to conquer cancer and save lives.
Amunix has designed the XPAT™ platform using its longstanding and validated XTEN technology as a mask for T cell engagers (TCEs). When combined with our proprietary protease release sites, we can selectively unleash the potent activity of TCEs in the tumor by taking advantage of the high protease activity in the tumor microenvironment.
April 12, 2021
Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety